{"nctId":"NCT00541775","briefTitle":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","startDateStruct":{"date":"2006-06"},"conditions":["Type 2 Diabetes Mellitus"],"count":273,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Comparator: Metformin"]},{"label":"Rosiglitazone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: Rosiglitazone","Drug: Comparator: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: Comparator: Metformin"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia"]},{"name":"Comparator: Rosiglitazone","otherNames":["Avandia"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"Comparator: Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has Type 2 diabetes\n* Currently taking metformin \\>1500 mg/day for at least 10 weeks\n* Male or female\n\nExclusion Criteria:\n\n* Patient has peripheral edema\n* History of type 1 diabetes\n* Patient required insulin within prior 8 weeks\n* Have participated or are currently participating in another study with an investigational compound or device within 12 weeks of starting this study\n* Participating in a weight loss program","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin A1C (A1C) at Week 18","description":"A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.\n\nThe study hypothesis comparison was between sitagliptin versus placebo.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":null},{"groupId":"OG001","value":"-0.79","spread":null},{"groupId":"OG002","value":"-0.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) at Week 18","description":"The change from baseline is the Week 18 FPG minus the Week 0 FPG.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":null},{"groupId":"OG001","value":"-24.5","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"2-hour Post-meal Glucose (PMG) at Week 18","description":"The change from baseline is the Week 18 PMG minus the Week 0 PMG.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.4","spread":null},{"groupId":"OG001","value":"-51.3","spread":null},{"groupId":"OG002","value":"-4.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":94},"commonTop":["Blood glucose increased"]}}}